These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17851230)

  • 21. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis.
    Higuchi C; Nishimura H; Sanaka T
    Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
    Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
    Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization.
    Santamaría B; Ucero AC; Reyero A; Selgas R; Ruiz-Ortega M; Catalán M; Egido J; Ortiz A
    Nephrol Dial Transplant; 2008 Oct; 23(10):3307-15. PubMed ID: 18524790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome.
    Jiménez C; Díaz C; Selgas R; Auxiliadora Bajo M; del Peso G; Sánchez-Tomero JA; Gonzalez-Gancedo P
    Adv Perit Dial; 1999; 15():36-9. PubMed ID: 10682069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute effects of peritoneal dialysis solutions in the mesenteric microcirculation.
    Frajewicki V; Brod V; Kushnir D; Kohan R; Bitterman H
    Transl Res; 2009 May; 153(5):249-56. PubMed ID: 19375686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Changes in peritoneal mesothelial cells in patients on peritoneal dialysis].
    Stojimirović B; Trpinac D; Obradović M; Milutinović D; Obradović D; Nesić V
    Med Pregl; 2001; 54(5-6):219-23. PubMed ID: 11759215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dialysate CA125 levels in stable peritoneal dialysis patients.
    Okada T; Nakao T; Matsumoto H
    Clin Nephrol; 1999 Jan; 51(1):65-6. PubMed ID: 9988153
    [No Abstract]   [Full Text] [Related]  

  • 28. Fate of the glucose degradation products 3-deoxyglucosone and glyoxal during peritoneal dialysis.
    Tauer A; Bender TO; Fleischmann EH; Niwa T; Jörres A; Pischetsrieder M
    Mol Nutr Food Res; 2005 Jul; 49(7):710-5. PubMed ID: 15915443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initiation of glucose-based peritoneal dialysis is associated with increased prevalence of metabolic syndrome in non-diabetic patients with end-stage renal disease.
    Jiang N; Qian J; Lin A; Lindholm B; Axelsson J; Yao Q
    Blood Purif; 2008; 26(5):423-8. PubMed ID: 18776721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.
    Krediet RT
    Perit Dial Int; 2001; 21(6):560-7. PubMed ID: 11783764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage.
    Nakamura S; Niwa T
    J Am Soc Nephrol; 2005 Jan; 16(1):144-50. PubMed ID: 15563557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cellular contribution to effluent potassium and its relation to free water transport during peritoneal dialysis.
    Coester AM; Struijk DG; Smit W; de Waart DR; Krediet RT
    Nephrol Dial Transplant; 2007 Dec; 22(12):3593-600. PubMed ID: 17664179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients.
    Redahan L; Davenport A
    J Nephrol; 2016 Jun; 29(3):427-434. PubMed ID: 26616639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dialysate cancer antigen 125 levels in children treated with peritoneal dialysis.
    Bouts AH; Groothoff JW; van Amstel SP; Zweers MM; Davin JC; Krediet RT
    Adv Perit Dial; 2000; 16():328-31. PubMed ID: 11045322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucotoxicity in peritoneal dialysis--solutions for the solution!
    Holmes CJ
    Adv Chronic Kidney Dis; 2007 Jul; 14(3):269-78. PubMed ID: 17603981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protecting the peritoneal membrane in dialyzed patients.
    Grzegorzewska AE
    Adv Med Sci; 2006; 51():191-6. PubMed ID: 17357307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis.
    Sanusi AA; Zweers MM; Weening JJ; de Waart DR; Struijk DG; Krediet RT
    Perit Dial Int; 2001; 21(5):495-500. PubMed ID: 11757834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The TGF-beta-induced gene product, betaig-h3: its biological implications in peritoneal dialysis.
    Park SH; Choi SY; Kim MH; Oh EJ; Ryu HM; Kim CD; Kim IS; Kim YL
    Nephrol Dial Transplant; 2008 Jan; 23(1):126-35. PubMed ID: 17704110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation, neoangiogenesis and fibrosis in peritoneal dialysis.
    de Lima SM; Otoni A; Sabino Ade P; Dusse LM; Gomes KB; Pinto SW; Marinho MA; Rios DR
    Clin Chim Acta; 2013 Jun; 421():46-50. PubMed ID: 23466603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid.
    Simonsen O; Wieslander A; Landgren C; Rippe B
    Adv Perit Dial; 1996; 12():156-60. PubMed ID: 8865892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.